Status:
COMPLETED
Extremely Premature Births During the Peak of the COVID-19 Pandemic: an International Study of the Active SafeBoosC III Departments
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Extreme Prematurity
Covid19
Eligibility:
All Genders
22-28 years
Brief Summary
This is a retrospective, observational study based on the consortium of the SafeBoosC-III randomised clinical trial. This study will evaluate if the number of admitted extremely preterm infants has de...
Detailed Description
On the 11th of March 2020, COVID-19 was declared a pandemic by the World Health Organisation, which led to an almost worldwide lockdown (1). During the lockdown, reductions in preterm birth rates and ...
Eligibility Criteria
Inclusion
- Extremely low gestational age neonates admitted to participating NICUs
Exclusion
- \-
Key Trial Info
Start Date :
August 21 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 13 2020
Estimated Enrollment :
885 Patients enrolled
Trial Details
Trial ID
NCT04527601
Start Date
August 21 2020
End Date
September 13 2020
Last Update
October 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neonatalklinikken, Rigshospitalet
Copenhagen, Denmark